Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03141671

Recruitment Status : Active, not recruiting

First Posted : May 5, 2017

Last Update Posted : May 14, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Janssen Pharmaceutica

Information provided by (Responsible Party):

Paul Nguyen, MD, Dana-Farber Cancer Institute

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	April 5, 2025
Estimated Study Completion Date :	December 31, 2025

To Top